Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001123292-26-000583 0002020620 XXXXXXXX LIVE 1 Common stock, par value $0.001 per share (the "Common Stock") 05/15/2026 false 0001563577 36338D108 Galera Therapeutics, Inc. 101 Lindenwood Drive, Suite 225 Malvern PA 19355 Timothy Opler 650-862-3029 c/o Emerald Bioventures, LLC 555 Madison Avenue, Suite 11D New York NY 10022 0002020620 Emerald Bioventures, LLC OO DE 0 61029978 0 61029978 61029978 N 30.2 CO 0001706867 Timothy Opler OO X1 0 61029978 0 61029978 61029978 N 30.2 IN Common stock, par value $0.001 per share (the "Common Stock") Galera Therapeutics, Inc. 101 Lindenwood Drive, Suite 225 Malvern PA 19355 This Amendment No. 1 to Schedule 13D ("Amendment No. 1") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission by the Reporting Persons on April 27, 2026 ("Original 13D"), relating to the Common Stock of the Issuer. Capitalized terms used in this Amendment No. 1 but not otherwise defined shall have the respective meanings ascribed to them in the Original 13D. Item 3 of the Original 13D is supplemented and amended, as the case may be, as follows: The response to Item 4 of this Amendment No. 1 is incorporated herein by reference. Item 4 of the Original 13D is supplemented and amended, as the case may be, as follows: On May 14, 2026, the Issuer provided Emerald with a Notice of Mandatory Conversion of Series B Non-Voting Convertible Preferred Stock (the "Mandatory Conversion Notice") effective May 15, 2026 (the "Mandatory Conversion"). In connection with the Mandatory Conversion, 20,813.8186192892 shares of Series B Preferred Stock held by Emerald were converted into 20,813,818 shares of Common Stock. In lieu of fractional shares to which Emerald was entitled, the Company is required to pay Emerald an amount of cash equal to such fraction multiplied by the closing price of a share of Common Stock on the applicable Trading Market (as defined in the Certificate of Designation) on the date of the Mandatory Conversion, in accordance with Section 6.4.6 of the Certificate of Designation. Following the Mandatory Conversion, the Emerald now holds 61,029,978 shares of Common Stock and no shares of Series B Preferred Stock. Item 5(a) of the Original 13D is hereby amended and restated in its entirety as follows: As of the date hereof, the Reporting Persons may be deemed to beneficially own 61,029,978 shares of Common Stock, representing approximately 30.2% of the shares of Common Stock outstanding. The percentage set forth in Row 13 is based on an aggregate of 203,268,886 shares of Common Stock outstanding, which reflects (a) 160,429,783 shares of Common Stock outstanding as of May 12, 2026, as reported in the Issuer's Quarterly Report on Form 10 Q filed on May 14, 2026, and (b) 42,839,103 shares of Common Stock issued upon the conversion of the Issuer's Series B Preferred Stock on May 15, 2026, as reported in the Issuer's Current Report on Form 8 K filed on May 15, 2026. Following such conversion, the Reporting Persons beneficially owned an aggregate of 61,029,978 shares of Common Stock. Item 5(a) of the Original 13D is hereby amended and restated in its entirety as follows: Except as otherwise set forth herein, the Reporting Persons have not effected any transactions in the Common Stock during the past 60 days of each of May 15, 2026 and the date hereof. Item 7 of the Original 13D is hereby amended and restated in its entirety as follows: Exhibit Description Exhibit 99.1 - Purchase Agreement, dated as of December 30, 2024 (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the SEC on December 31, 2024).* Exhibit 99.2 - Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the SEC on December 31, 2024).* Exhibit 99.3 - Form of Galera Stockholder Support Agreement (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the SEC on April 14, 2026).* Exhibit 99.4 - Joint Filing Agreement. * Previously filed Emerald Bioventures, LLC /s/ Timothy Opler Timothy Opler, Managing Member 05/29/2026 Timothy Opler /s/ Timothy Opler Timothy Opler 05/29/2026